Holmes Defends Theranos' 'Aggressive' IP Protection At Trial
By Dorothy Atkins (December 7, 2021, 11:15 PM EST) -- Ex-Theranos CEO Elizabeth Holmes' cross-examination in her criminal fraud trial wrapped Tuesday, with Holmes conceding that she didn't tell investors Theranos was performing blood tests on modified third-party devices but defending that and other sometimes "aggressive" actions as necessary to protect the startup's trade secrets.
During the second day of Holmes' cross-examination, prosecutor Robert Leach probed the 37-year-old former Silicon Valley executive on her knowledge of issues with Theranos' blood tests. Holmes repeatedly acknowledged that she never told investors that Theranos was using devices made by Siemens and other companies, which Theranos engineers began modifying in 2013 to run blood tests for Walgreens....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!